Ampio announces active IND for Optina for treatment of DME Ampio Pharmaceuticals announced that the FDA has accepted the company's IND for Optina for the treatment of Diabetic Macular Edema, or DME. Ampio plans to commence enrollment in a clinical trial in Q1. The FDA granted Optina 505 b 2 status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
Ampio confirms sales agreement with Cantor Fitzgerald Ampio Pharmaceuticals entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. CEO Michael Macaluso stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."